The complement system in liposome clearance: Can complement deposition be inhibited?

Advanced Drug Delivery Reviews

Volumn 32, Issue 1-2, 1998, Pages 19-29

  Devine, Dana V ^a   Bradley, Amanda J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Complement; Complement inhibition; Liposome; Liposome clearance

Indexed keywords

DRUG INTERACTIONS; PROTEINS;

COMPLEMENT SYSTEMS; LIPOSOMES;

CONTROLLED DRUG DELIVERY;

LECTIN; LIPOSOME;

COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; DRUG CLEARANCE; LYSIS; OPSONIZATION; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW;

EID: 0032496674     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00129-4     Document Type: Review

References (67)

1. B.P. Morgan, Complement: Clinical Aspects and Relevance to Disease, Academic Press, San Diego, 1990.
2. Devine D.V. The regulation of complement on cell surfaces. Transfus. Med. Rev. 5:1991;123-131.
3. Reid K.B.M. Activation and control of the complement system. Essay Biochem. 22:1986;27-68.
4. Rent R., Ertel N., Eisenstein R., Gewurz H. C activation by interaction of polyanions and polycations. I. Heparin-protamine induced consumption of complement. J. Immunol. 114:1975;120-124.
5. Agnello V., Winchester R.J., Kunkel H.G. Precipitin reactions of C1q with aggregated gamma-globulin, and immune complexes in gel diffusion. Immunology. 19:1970;909-919.
6. Marjan J., Xie Z., Devine D.V. Liposome-induced activation of the classical complement pathway does not require immunoglobulin. Biochim. Biophys. Acta. 1192:1994;35-44.
7. Osmand A.P., Friedenson B., Gewurz H., Painter R.H., Hofmann T., Shelton T.E. Characterization of C-reactive protein and the complement component C1t and homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc. Natl. Acad. Sci. USA. 74:1977;739-743.
8. Pepys M.B., Baltz M.L., deBeer F.C., Dyck R.F., Holford S., Breathnach S.M., Black M.M., Tribe C.R., Evans D.J., Feinstein A. Biology of serum amyloid P component. Ann. New York Acad. Sci. 389:1982;286-298.
9. Pepys M.B., Blatz M.L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein. Adv. Immunol. 34:1983;141-212.
10. Bristow C.L., Boackle R.J. Evidence for the binding of human serum amyloid P component to C1q and Fab. Mol. Immunol. 23:1986;1045-1052.
11. Ying S.-C., Gewurz A.T., Jiang H., Gewutz H. Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q. J. Immunol. 150:1993;169-176.
12. Volanakis J.E., Kaplan M.H. Specificity of C-reactive proteins for choline phosphate residues of pneumococcal C-polysaccharide. Proc. Soc. Exp. Biol. Med. 136:1971;612-614.
13. Kaplan M.H., Volanakis J.E. Interactions of C-reactive protein with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J. Immunol. 112:1974;2135-2147.
14. Volanakis J.E., Wirtz K.W.A. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature. 281:1979;155-157.
15. DiCamelli R., Potempa L.A., Siegel J., Suyehira L., Petras K., Gewurz H. Binding reactivity of C-reactive protein for polycations. J. Immunol. 125:1980;1933-1938.
16. Lu J.H., Thiel S., Wiedemann H., Timpl R., Reid K.B. Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1r2C1s2 complex of the classical pathway of complement, without involvement of C1q. J. Immunol. 144:1990;2287-2294.
17. Ikeda K., Sannoh T., Kawasaki N., Kawasaki T., Yamashina I. Serum lectin with known structure activates complement through the classical pathway. J. Biol. Chem. 262:1987;7451-7454.
18. Ohta M., Okada M., Yamashina I., Kawasaki T. The mechanism of carbohydrate-mediated complement activation by the serum mannan-binding protein. J. Biol. Chem. 265:1990;1980-1984.
19. Ji Y.H., Matsushita M., Okada H., Fujita T., Kawakami M. The C4 and C2 but not C1 components of complement are not responsible or the complement activation triggered by the Ra-reactive factor. J. Immunol. 141:1988;4271-4275.
20. Super M., Levinsky R.J., Turner M.W. The level of mannan-binding protein regulates the binding of complement-derived opsonins to mannan and zymosan at low serum concentrations. Clin. Exp. Immunol. 79:1990;144-150.
21. Schweinle J.E., Ezekowitz R.A.B., Tenner A.J., Kuhlman M., Joiner K.A. Human mannose-binding protein activates the alternative complement pathway and enhances serum bactericidal activity on a mannose-rich isolate of salmonella. J. Clin. Invest. 84:1989;1821-1829.
22. Kinoshita T. Protection of host from its own complement by membrane-bound complement inhibitors: C3 convertase inhibitors vs membrane attack complex inhibitors. Res. Immunol. 147:1996;100-103.
23. H. Harashima, H. Matsuo, H. Kiwada, Identification of proteins mediating clearance of liposomes using a liver perfusion system, Adv. Drug Deliv. Rev., this issue.
24. S.M. Moghimi, H.M. Patel, Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity, Adv. Drug Deliv. Rev., this issue.
25. G.L. Scherphof, J.A.A.M. Kamps, Receptor versus non-receptor mediated clearance of liposomes, Adv. Drug Deliv. Rev., this volume.
26. Galanos C., Rietschel E.T., Luderitz O., Westphal O. Interaction of lipopolysaccharides and lipid A with complement. Eur. J. Biochem. 19:1971;143-152.
27. Shin M.L., Paznekas W.A., Mayer M.M. On the mechanism of membrane damage by complement: The effect of length and unsaturation of the acyl chains in liposomal bilayers and the effect of cholesterol concentration in sheep erythrocyte and liposomal membranes. J. Immunol. 120:1978;1996-2002.
28. Thielens N.M., Colomb M.G. A model system for the study of the assembly and regulation of human complement C3 convertase (classical pathway). Eur. J. Immunol. 16:1986;617-622.
29. Kovacsovics T., Tschopp J., Kress A., Isliker H. Antibody-independent activation of C1, the first component of complement, by cardiolipin. J. Immunol. 135:1985;2695-2700.
30. Cunningham C.M., Kingzette M., Richards M.L., Alving C.R., Lint T.F., Gewurz H. Activation of human complement by liposomes: A model for membrane activation of the alternative pathway. J. Immunol. 122:1979;1237-1242.
31. Liu Z.Y., Solow R., Hu V.W. Fluorescence analysis of size distribution and mode of dye release from carboxyfluorescein-loaded vesicles: Application to the study of complement-membrane interactions. Biochim. Biophys. Acta. 945:1988;253-262.
32. Volanakis J.E., Narkates A.J. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. J. Immunol. 126:1981;1820-1825.
33. Mold C., Gewurz H. Inhibitory effect of C-reactive protein on alternative C pathway activation by liposomes and Streptococcus pneumoniae. J. Immunol. 127:1981;2089-2092.
34. Richards R.L., Gewurz H., Osmand A.P., Alving C.R. Interactions of C-reactive protein and complement with liposomes. Proc. Natl. Acad. Sci. USA. 74:1977;5672-5676.
35. Richards R.L., Gewurz H., Siegel J., Alving C.R. Interactions of C-reactive protein and complement with liposomes. II. Influence of membrane composition. J. Immunol. 122:1979;1185-1189.
36. Schwalbe R.A., Dahlback B., Coe J.E., Nelsestuen G.L. Pentraxin family of proteins interact specifically with phosphorylcholine and/or phosphorylethanolamine. Biochemistry. 31:1992;4907-4915.
37. Juliano R.L., Stamp D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem. Biophys. Res. Commun. 63:1975;651-658.
38. R.L. Juliano, G. Lin, The interaction of plasma proteins with liposomes: Protein binding and the effects of the clotting and complement system, in: B.H. Tom, H.R. Six (Eds.), Liposomes and Immunobiology, Elsevier-North-Holland, Amsterdam, 1980.
39. Alving C.R., Richards R.L., Guirguis A.A. Cholesterol dependent human complement activation resulting in damage to liposomal model membranes. J. Immunol. 118:1977;342-347.
40. Okada N., Yasuda T., Tsumita T., Okada H. Differing reactivities of human and guinea pig complement on haptenized liposomes via the alternative pathway. Mol. Immunol. 20:1983;857-864.
41. Okada N., Yasuda T., Tsumita T., Okada H. Activation of the alternative complement pathway of guinea pig by liposomes incorporated with trinitrophenylated phosphatidylethanolamine. Immunology. 45:1982;115-124.
42. Richards R.L., Habbersett R.C., Scher I., Janoff A.S., Schieren H.P., Mayer L.D., Cullis P.R., Alving C.R. Influence of vesicle size on complement-dependent immune damage to liposomes. Biochim. Biophys. Acta. 855:1986;223-230.
43. Roerdink F., Wassef N.M., Richardson E.C., Alving C.R. Effects of negatively charged lipids on phagocytosis of liposomes opsonized by complement. Biochim. Biophys. Acta. 734:1983;33-39.
44. Harashima H., Sakata K., Funato K., Kiwada H. Enhanced uptake of liposomes through complement activation depending on the size of liposomes. Pharm. Res. 11:1994;402-406.
45. Matsuo H., Funato K., Harashima H., Kiwada H. The complement- but not mannose receptor-mediated phagocytosis is involved in the hepatic uptake of cetylmannoside-modified liposomes in situ. J. Drug Targeting. 2:1994;141-146.
46. Liu D., Liu F., Song Y.K. Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonin. Biochim. Biophys. Acta. 1235:1995;140-146.
47. Patel H.M. Serum opsonins and liposomes: Their interaction and opsonophagocytosis. Crit. Rev. Ther. Drug Carrier Syst. 9:1992;39-90.
48. Chonn A., Cullis P.R., Devine D.V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 146:1991;4234-4241.
49. Devine D.V., Wong K., Serrano K., Chonn A., Cullis P.R. Liposome-complement interactions in rat serum: Implications for liposome survival studies. Biochim. Biophys. Acta. 1191:1994;43-51.
50. Devine D.V., Marjan J.M.J. The role of immunoproteins in the survival of liposomes in the circulation. Crit. Rev. Ther. Drug Carrier Syst. 14:1997;105-131.
51. Jiang H., Robey F.A., Gewurz H. Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain. J. Exp. Med. 175:1992;1373-1379.
52. Harashima H., Ochi Y., Kiwada H. Kinetic modeling of liposome degradation in serum: Effect of size and concentration of liposomes in vitro. Biopharm. Drug Dispos. 15:1994;217-225.
53. Wassef N.A., Johnson S.H., Graeber G.M., Swartz G.M., Schultz C.L., Hailey J.R., Johnson A.J., Taylor D.G., Ridgway R.L., Alving C.R. Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs. J. Immunol. 143:1989;2990-2995.
54. Loughrey H.C., Bally M.B., Reinish L.W., Cullis P.R. The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement. Thromb. Haemostas. 64:1990;172-176.
55. P.C. Ghosh, B.K. Bachhawat, Effect of surface modification with glycolipids and polysaccharides on in vivo fate of liposomes, in: D. Lasic, F. Martin (Eds.), Stealth Liposomes, CRC Press, Boca Raton, FL., 1995, pp. 13-24.
56. Liu D., Song Y.K., Liu F. Antibody dependent, complement mediated liver uptake of liposomes containing GM1. Pharm. Res. 12:1995;1775-1780.
57. Allen T.M., Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 23:1987;42-48.
58. Funato K., Yoda R., Kiwada H. Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. Biochim. Biophys. Acta. 1103:1992;198-204.
59. Spiller O.B., Morgan B.P., Tufaro F., Devine D.V. Altered expression of host-encoded complement regulators on HCMV-infected cells. Eur. J. Immunol. 26:1996;1532-1538.
60. Marschang P., Sodroski J., Wurzner R., Dierich M.P. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur. J. Immunol. 25:1995;285-290.
61. Rother R.P., Squinto S.P., Mason J.M., Rollins S.A. Protection of retroviral vector particles in human blood through complement inhibition. Hum. Gene Ther. 6:1995;429-435.
62. Ryan U.S. Complement inhibitory therapeutics and xenotransplantation. Nature Med. 1:1995;967-968.
63. Okada N., Tanaka H., Takizawa H., Okada H. A monoclonal antibody that blocks the complement regulatory activity of guinea pig erythrocytes and characterization of the antigen involved as guinea pig decay-accelerating factor. J. Immunol. 154:1995;6103-6111.
64. Sahu A., Kay B.A., Lambris J.D. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J. Immunol. 157:1996;884-891.
65. Thomas H., Maillet F., Letourneur D., Jozefonvica J., Fischer E., Kazatchkine M.D. Sulfonated dextran inhibits complement activation and complement-dependent cytotoxicity in an in vitro model of hyperacute xenograft rejection. Mol. Immunol. 33:1996;643-648.
66. Mold C. Effect of membrane phospholipids on activation of the alternative complement pathway. J. Immunol. 143:1989;1663-1668.
67. Comis A., Easterbrook-Smith S.B. Inhibition of serum complement haemolytic activity by lipid vesicles containing phosphatidylserine. FEBS Lett. 197:1986;321-327.